A detailed history of Northern Trust Corp transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 438,341 shares of ATXS stock, worth $4.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
438,341
Previous 416,260 5.3%
Holding current value
$4.07 Million
Previous $3.79 Million 27.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.97 - $12.65 $198,066 - $279,324
22,081 Added 5.3%
438,341 $4.83 Million
Q2 2024

Aug 14, 2024

SELL
$8.83 - $13.51 $120,379 - $184,181
-13,633 Reduced 3.17%
416,260 $3.79 Million
Q1 2024

May 14, 2024

BUY
$6.99 - $16.69 $886,269 - $2.12 Million
126,791 Added 41.83%
429,893 $6.05 Million
Q4 2023

Feb 13, 2024

BUY
$4.42 - $8.06 $259,679 - $473,533
58,751 Added 24.04%
303,102 $2.33 Million
Q3 2023

Nov 13, 2023

BUY
$6.89 - $9.86 $799 - $1,143
116 Added 0.05%
244,351 $1.82 Million
Q2 2023

Aug 11, 2023

BUY
$8.33 - $13.72 $1.64 Million - $2.7 Million
196,712 Added 413.93%
244,235 $2.03 Million
Q1 2023

May 15, 2023

BUY
$11.2 - $15.79 $236,140 - $332,916
21,084 Added 79.75%
47,523 $632,000
Q4 2022

Feb 13, 2023

BUY
$7.44 - $14.89 $50,934 - $101,936
6,846 Added 34.94%
26,439 $393,000
Q3 2022

Nov 14, 2022

SELL
$2.97 - $10.34 $938 - $3,267
-316 Reduced 1.59%
19,593 $177,000
Q2 2022

Aug 12, 2022

SELL
$2.46 - $6.96 $467 - $1,322
-190 Reduced 0.95%
19,909 $60,000
Q1 2022

May 13, 2022

SELL
$3.92 - $7.1 $7,502 - $13,589
-1,914 Reduced 8.69%
20,099 $135,000
Q4 2021

Feb 08, 2022

BUY
$5.08 - $8.62 $14,020 - $23,791
2,760 Added 14.34%
22,013 $119,000
Q3 2021

Nov 15, 2021

BUY
$7.32 - $12.9 $140,931 - $248,363
19,253 New
19,253 $170,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $141M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.